GlassScriptPhysician profile
Ravitej Khunkhun
NPI 1902875487
$2,914.08
in general payments reported to CMS, 2019-2025
19 companies · $200 in 2025
The $200 reported for 2025 was more than what 76% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $164 · 2021: $401 · 2022: $518 · 2023: $665 · 2024: $490 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $718.64 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $623.82 | 2019-2024 | Eliquis, Camzyos |
| Pfizer INC. | $289.28 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $203.42 | 2019-2024 | Lifevest |
| Alexion Pharmaceuticals, INC. | $188.85 | 2021-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $184.92 | 2019-2024 | |
| Abbvie INC. | $145.45 | 2021-2025 | |
| Gilead Sciences, INC. | $85.58 | 2021 | |
| Allergan, INC. | $71.14 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $69.87 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.68 | 2024-2025 | Xifaxan |
| Actelion Pharmaceuticals US, INC. | $64.40 | 2022-2024 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.55 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $39.03 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $34.14 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $31.54 | 2024-2025 | |
| Novo Nordisk INC | $22.09 | 2024 | Wegovy |
| Recordati_rare_diseases_inc. | $18.62 | 2024 | Panhematin |
| Paratek Pharmaceuticals, INC. | $18.06 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravitej Khunkhun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.